{
    "clinical_study": {
        "@rank": "117704", 
        "acronym": "RECORA", 
        "arm_group": {
            "arm_group_label": "Regorafenib", 
            "description": "Patients treated with Stivarga, no intervention"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to investigate the safety and effectiveness of Stivarga in\n      patients with metastatic colorectal carcinoma in routine use in Germany. The study is purely\n      observational, only data from routine treatment are to be collected. The treatment and\n      treatment conditions are solely at discretion of the treating physician."
        }, 
        "brief_title": "Investigating the Use of Regorafenib (Stivarga\u00ae) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Neoplasm", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\u00b4\n\n          -  Male or female patients \u2265 18 years of age with metastatic CRC for whom the decision\n             has been taken by the investigator to treat with Stivarga.\n\n          -  Patients must have signed an informed consent form\n\n        Exclusion Criteria:"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Female and male patients \u2265 18 years of age with a diagnosis of metastatic colorectal\n        carcinoma (mCRC) will be enrolled in the sites during the enrollment period. All treatment\n        decisions prior inclusion of a patient as well as during the observation must be made by\n        the investigator based on his regular medical practice. Patients must give written\n        informed consent prior to documentation."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959269", 
            "org_study_id": "16665", 
            "secondary_id": "SV1313"
        }, 
        "intervention": {
            "arm_group_label": "Regorafenib", 
            "description": "As determined by the treating physician", 
            "intervention_name": "Regorafenib (Stivarga, BAY 73-4506)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 19, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Germany"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "RECORA- Regorafenib in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "after 36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959269"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "after 36 months"
            }, 
            {
                "measure": "Time to progression", 
                "safety_issue": "No", 
                "time_frame": "after 36 months"
            }, 
            {
                "description": "Disease control rate (DCR) is defined as percentage of patients, whose best response was not progressive disease (i.e. complete response, partial response or stable disease).", 
                "measure": "Disease control rate (DCR)", 
                "safety_issue": "No", 
                "time_frame": "after 36 months"
            }, 
            {
                "description": "Duration of Stivarga treatment is defined as the time interval from start of Stivarga therapy to the date of permanent discontinuation of Stivarga therapy (regardless of the reason for discontinuation)", 
                "measure": "Duration of Stivarga treatment", 
                "safety_issue": "No", 
                "time_frame": "after 36 months"
            }, 
            {
                "description": "The tumor status at different visits will be evaluated according to the categories \"complete response\", \"partial response\", \"stable disease\", \"progressive disease by clinical judgment\", \"progressive disease measurement proven\", \"unknown\" and \"not applicable\". The best overall response will be analyzed providing absolute and relative frequencies of the tumor status categories.", 
                "measure": "Tumor status at different visits", 
                "safety_issue": "No", 
                "time_frame": "after 36 months"
            }, 
            {
                "description": "Detailed information collected for each TEAE will include: a description of the event, duration, whether the TEAE was serious, relationship to Stivarga, action taken, clinical outcome. Summary tables will present the number of subjects observed with TEAEs and corresponding percentages. Additional subcategories will be based on event intensity and relationship to study drug.", 
                "measure": "Incidence of treatment emergent adverse events (TEAE)", 
                "safety_issue": "Yes", 
                "time_frame": "after 18 and 36 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}